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Abstract 
The Linker of Nucleoskeleton and Cytoskeleton (LINC) complex mediates intracellular crosstalk 
between the nucleus and the cytoplasm. In striated muscle, the LINC complex provides structural 
support to the myocyte nucleus and plays an essential role in regulating gene expression and 
mechanotransduction. A wide range of cardiac and skeletal myopathies have been linked to mutations 
in LINC complex proteins. Studies utilizing tissue-specific knockout and mutant mouse models have 
revealed important insights into the roles of the LINC complex in striated muscle. In this chapter, we 
describe several feasible approaches for generating striated muscle-specific gene knockout and mutant 
mouse models to study LINC complex protein function in cardiac and skeletal muscle. The 
experimental procedures used for phenotyping and analysis of LINC complex knockout mice are also 
described. 
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1. Introduction 
The application of gene targeting technology to create modifications in a tissue-specific manner and at 
a precise stage in development is a powerful tool to elucidate the functions of Linker of Nucleoskeleton 
and Cytoskeleton (LINC) complex proteins in vivo. Targeting specific genes for modification by 
homologous recombination in embryonic stem (ES) cells has become a routine procedure (Muller, 
1999; van der Weyden et al., 2002). Over the past decade, we have routinely reported the use ES cell 
gene targeting technology to generate null or point mutation alleles in the study of LINC complex 
protein function (Banerjee et al., 2014; Chapman et al., 2014; Stroud et al., 2017; Zhang et al., 2010). 
More recently, a growing body of studies has utilized clustered regulatory interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology to generate genetically modified 
mice with extraordinary simplicity and speed (Aida et al., 2015; Hashimoto et al., 2016; Ma et al., 2017; 
Nakagawa et al., 2016; Wang et al., 2013). Here, we briefly describe the methodology of traditional 
gene targeting (Figure 1), and report in detail a cloning-free method to successfully generate floxed, as 
well as single-amino-acid-substituted mice that can be used for striated muscle-specific gene targeting 
of LINC complex proteins. The general approaches and techniques described here can also be applied 
to establish other gene knockout and mutant mouse models. 
 
1.1 Generation of floxed mice 
Conditional knockout of a target gene in mice is based on generating a floxed allele by inserting two 
34 base pair (bp) sequences of DNA referred to as LoxP sites that flank either side of a critical exon in 
a gene of interest. The LoxP sites are recognized by a Cre-recombinase, which mediates 
recombination to excise the floxed exon and achieve gene inactivation (Banerjee et al., 2014; Kilby et 
al., 1993; Kuhn et al., 1995; Rajewsky et al., 1996).  
 
Many of the genes encoding the LINC complex are available as floxed alleles on the International 
Mouse Phenotype Consortium (IMPC) website (https://www.mousephenotype.org/data/search), which 
greatly expedites the process of generating conditional null alleles. Generally, the IMPC mouse lines 
contain the desired floxed allele with LacZ and Neomycin cassettes still present (Figure 1A) (Note 1), 
which are removed by crossing the mice with a flpase (FLP) deleter mouse (Rodriguez et al., 2000). 
Alternatively, global or conditional tissue-specific knockout mice can be generated by crossing the 
IMPC mice with a desired Cre deleter mouse (Figure 1A and Section 1.3). For mouse lines unavailable 
through the IMPC website, two approaches can be used to generate floxed alleles as outlined below.  
 
(1) Traditional gene targeting 
In traditional gene targeting, a conditional construct is first generated (Figure 1B) (Note 2, 3), linearized 
with a restriction enzyme, and electroporated into ES cells. Targeted ES cells are identified by Southern 
blot analysis. ES cells from a homologous recombinant clone are then microinjected into mouse 
blastocysts. Male chimeras are bred with female breeder mice to generate germline-transmitted 
heterozygous mice with a neomycin cassette, which are confirmed by PCR or Southern blot analysis of 
mouse-tail DNA (Banerjee et al., 2014; Chapman et al., 2014; Liang et al., 2005; Stroud et al., 2017; 
Zhang et al., 2010).  
 
(2) Cloning-free CRISPR/Cas9-mediated gene manipulation 
In this chapter we focus on the clustered regulatory interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated protein 9 (Cas9) system as a powerful tool to generate striated muscle-
specific gene knockout and mutant mouse models to study LINC complex protein function in cardiac 
and skeletal muscle. The CRISPR/Cas9 system consists of a Cas9 nuclease and two small 
RNAs: CRISPR RNA (crRNA), which acts as a guide for gene targeting, and trans-activating crRNA 
(tracrRNA), which binds to crRNA and forms a ribonucleoprotein complex with Cas9 to direct 
sequence-specific double-stranded breaks (DSBs) (Chylinski et al., 2013; Deltcheva et al., 2011; Jinek 
et al., 2012). Recently, we developed a cloning-free method to generate floxed alleles by pronuclear 
injection of a commercial Cas9 protein:crRNA:tracrRNA:single-strand oligodeoxynucleotide (ssODN) 
complex into mouse zygotes (Ma et al., 2017) (Figure 2A). In this method, two crRNAs are designed to 
direct the Cas9 to target the upstream and downstream introns of the target exon, along with 
corresponding LoxP site oligos with 60 bp homology sequences on either side surrounding each Cas9-
mediated DSB (Figure 2B).  
 
1.2 Generation of single amino-acid-substituted mutant mice 
Whereas conditional knockout strategies are ideal for understanding protein function in a tissue-specific 
manner, the generation of mouse models that recapitulate human disease-causing single amino-acid 
substitutions using knock-in strategies are critical in the study of disease pathophysiology. Indeed, 
missense mutations in LINC complex proteins are a major cause of striated muscle disorders in 
humans (Bione et al., 1994; Bione et al., 1995; Christensen et al., 2011; Haque et al., 2010; 
Hodgkinson et al., 2013; Malhotra and Mason, 2009; Merner et al., 2008; Puckelwartz et al., 2010; 
Yamada and Kobayashi, 1996; Zhang et al., 2007). Similarly to conditional knockout strategies, two 
main strategies exist to generate single amino-acid-substituted mutant mice (Figure 1C). 
 
(1) Traditional gene targeting 
Similarly to the gene targeting approach described in Section 1.1(1), a targeting construct is used, 
except that the vector does not contain LoxP sites, but instead contains the mutated codon(s) (Fang et 
al., 2017a; Sheikh et al., 2012; Zhang et al., 2015). 
 
(2) Cloning-free CRISPR/Cas9-mediated gene manipulation 
Similarly to the generation of floxed alleles described in Section 1.1(2), a mixture of Cas9 protein, 
crRNA, tracrRNA, and ssODN are injected into the pronuclei of zygotes (Figure 2A), except that the 
sequence of the crRNA targets the Cas9 nuclease to the desired mutation-specific region of the target 
gene (Figure 2C) (Ma et al., 2017). Mutation-specific primers with a site-specific variant sequence at 
the 3’ terminus of the forward primer are used to screen for correctly targeted mice (Figure 2D). 
 
1.3 Generation of striated muscle-specific knockout or mutant mice by Cre recombination 
Tissue-specific knockout is achieved by crossing floxed mice with Cre mouse lines that express Cre 
recombinase under the control of a tissue-specific promoter or enhancer (Banerjee et al., 2014; Kilby et 
al., 1993; Kuhn et al., 1995; Rajewsky et al., 1996). The selection of an appropriate Cre expressing 
mouse line is a crucial step in the process of generating a striated muscle selective LINC complex 
protein knockout or mutant mice. Three criteria need to be considered: 1. Tissue and/or cell-selectivity 
of Cre expression; 2. Timing and duration of Cre expression; and 3. Efficiency of the Cre recombinase. 
Here, we discuss a number of Cre mouse lines used for the generation of striated muscle-specific 
knockout or mutant mice by Cre recombination. 
 
1.3.1 Cardiac-specific Cre lines 
 
(1) Constitutive Cre lines 
There are many cardiac-specific Cre lines available for ablating gene expression in cardiomyocytes 
(see Table 1 and references therein) (Davis et al., 2012). Here we describe those we have used in our 
studies of cardiac function. 
 
The most widely used Cre lines for inducing gene ablation in cardiomyocytes are those utilizing 
promoter regions from the alpha (α)-myosin heavy chain (MHC) gene (Abel et al., 1999; Agah et al., 
1997; Buerger et al., 2006). However, a potential caveat of using certain αMHC lines is that those with 
high levels of myocardial expression of Cre recombinase lead to dilated cardiomyopathy (Buerger et al., 
2006). In contrast and in our hands, the αMHC-Cre line developed by Dale Abel’s laboratory has shown 
no evidence of Cre toxicity (Fang et al., 2017b). 
 
As one of the earliest markers of heart progenitor cells, the regulatory regions of Nkx2.5 have been 
used to generate several Cre lines for inducing gene ablation during early cardiogenesis (McFadden et 
al., 2005; Moses et al., 2001; Stanley et al., 2002). In our experience, the Nkx2.5-Cre transgenic line 
developed by the Olson laboratory reduced the RNA level of Nesprin 1 by 88% in adult cardiomyocytes 
(Banerjee et al., 2014; McFadden et al., 2005). The Nkx2.5-Cre developed by the Harvey laboratory is 
also highly efficient, however it is expressed in derivatives of the pharyngeal endoderm, which include 
the stomach, spleen, pancreas and liver (Stanley et al., 2002). The Schwarz laboratory developed an 
Nkx2.5 knock-in Cre line, which is heterozygous null for Nkx2.5 (Moses et al., 2001). However, owing to 
the importance of the Nkx2.5 gene, these mice develop cardiac abnormalities (Biben et al., 2000; Jay et 
al., 2004). 
 
The cardiac troponin T (cTnT)-Cre line generated by Brigid Hogan’s laboratory, in which Cre is driven 
by the rat cTnT promoter, induces early recombination at E7.5 with high efficiency in cardiomyocytes 
(Jiao et al., 2003). In our experience of using this line, we achieved ~80% reduction at the protein level 
of the two floxed alleles, Numb and NumbL, from whole hearts at E10.5 (Hirai et al., 2017). For this line, 
it is important to maintain male breeders of a young age (<6 months of age) as older breeders develop 
a shorter stature and don’t reproduce as well (unpublished observations). 
 
Recently, the Mohun laboratory developed a Xenopus laevis Myosin Light Chain 2 promoter-driven Cre 
recombinase (XMLC2-Cre) that is functional in all myocardial cells throughout embryonic development 
and adulthood (Breckenridge et al., 2007). Importantly, the onset of recombinase activity occurs very 
early in cardiogenesis at the cardiac crescent stage. Given that the XMLC2-Cre mouse line has high 
efficiency, precise tissue-specificity, and is early onset, it is a powerful tool to achieve gene ablation in a 
myocardial-specific manner in both embryos and adults. 
 
Our laboratory generated a ventricle-restricted Cre line by knocking-in Cre into the myosin light chain 
2v (MLC2v) locus (Chen et al., 1998). This MLC2v-Cre mouse is heterozygous for MLC2v, but the mice 
are normal, display no morphogenic defects, and express normal levels of MLC2v protein (Minamisawa 
et al., 1999). The Cre recombinase expresses at the earliest stages of ventricular chamber 
specification, however, the efficiency of the recombinase is relatively low in embryonic ventricular 
cardiomyocytes (Chen et al., 1998; Shai et al., 2002). 
 
(2) Inducible Cre lines 
Temporal regulation of gene excision is highly desirable for studying gene function in the adult heart, 
especially if ablation during development results in embryonic lethality. This can be achieved through 
using inducible tamoxifen- or tetracycline-driven Cre lines (Table 1). 
 
The αMHC-MerCreMer transgenic line, in which the cardiac-specific αMHC promoter directs expression 
of tamoxifen-inducible Cre recombinase (MerCreMer) (Sohal et al., 2001), has been used extensively. 
We and others have shown that Cre activity is tightly regulated, and that Cre-mediated recombination 
occurs only in response to the injection of tamoxifen (Nakai et al., 2007; Zhang et al., 2016). There 
have been reports of tamoxifen treatment induced phenotypes using this line; therefore we recommend 
using αMHC-MerCreMer mice alone and/or αMHC-MerCreMer mice with the heterozygous floxed allele 
as controls (Bersell et al., 2013; Koitabashi et al., 2009; Lexow et al., 2013; Vogt et al., 2008). 
 
Recently, a tamoxifen-inducible cTnT-Cre was developed by introducing the MerCreMer cassette 
upstream of the first exon of the cTnT gene (Yan et al., 2015). Minimal Cre “leakiness” prior to 
tamoxifen injection and robust recombination in cardiomyocytes was reported 24 hours after 
administration. 
 
Tamoxifen administration alone may cause behavioral alterations, therefore dosage optimization is 
pertinent when using tamoxifen-inducible mouse lines (Vogt et al., 2008). As an alternative to 
tamoxifen, for cardiac-specific ablation we have used the tetracycline-inducible system developed by 
the Zhou laboratory. This approach uses the rat Troponin T promoter to express the reverse 
tetracycline-controlled transactivator, which in turn drives Cre expression via a tetracycline-responsive 
promoter (Hirai et al., 2017; Wu et al., 2010). 
 
1.3.2 Skeletal muscle-specific Cre lines 
A number of constitutive- and inducible- skeletal muscle-specific Cre mice have been developed (Table 
1). The Human α-Skeletal Actin (HSA) promoter has been used to drive constitutive (Miniou et al., 
1999), tamoxifen-inducible (McCarthy et al., 2012), and tetracycline-inducible (Rao and Monks, 2009) 
Cre expression. HSA-Cre expression is largely restricted to skeletal muscle; however, there is evidence 
of mosaicism between different skeletal muscle types, and evidence of low-level expression in the 
heart. 
 
Myogenin-Cre transgenic mice were developed by the Olson laboratory (Li et al., 2005) in which Cre 
expression is under the control of the mouse myogenin promoter and mouse myocyte enhancer factor 
2C (MEF2C) enhancer region. 
 
There are an extensive number of tamoxifen-inducible skeletal muscle knock-in Cre lines developed by 
the Lepper laboratory, which include Pax3, MyoD, Myog, Myf6 and Myl1, and have been well 
characterized (Southard et al., 2014). 
 
1.3.3 Generation of conditional knock-in mutant mice 
The strategies in Section 1.1(2) describe how to generate global knock-in mice. However, if 
homozygous mutant mice are not viable or unable to reproduce, tissue-specific mutant mice strategies 
can be employed to circumvent this. The Kontaridis laboratory generated Cre-dependent conditional 
knock-in mice harboring a Y279C mutant of the Ptpn11 gene (Marin et al., 2011). In this case, the 
Y279C mutant is only expressed after Cre-mediated excision. Therefore, a tissue-specific Cre could be 
used to drive expression only in the tissue of interest. As a simpler alternative, we crossed conditional 
knockout mice (f/f; Cre+) with heterozygous mutants (m/+) to generate conditional mutant mice (f/m; 
Cre+) mice (Fang et al., 2017b). Conditional mutant mice were subsequently crossed with floxed (f/f) 
mice to generate relevant control littermates (Figure 3) (Note 4). 
 
2. Materials 
 
2.1 CRISPR/Cas9-mediated gene manipulation to create floxed and point mutation mice with a 
cloning-free method 
 
2.1.1 CRISPR/Cas9 injection 
1. Mice. C57BL/6 J female mice at age 3-4 weeks and male mice at 9-24 weeks (Envigo) for 
zygote collection. ICR (CD-1) mice for pseudopregnant mother and vasectomized males 
(Envigo). 
2. Recombinant Cas9 proteins (New England BioLabs, Cat. No. M0386S). 
3. CrRNA and tracrRNA: Chemically synthesized, and RNase-Free HPLC purified (Integrated 
DNA Technologies). 
4. Single-strand ODN: Chemically synthesized and standard desalted (Integrated DNA 
Technologies). 
5. 1X TE Solution (Integrated DNA Technologies). 
6. Pregnant mare serum gonadotropin (PMSG; Sigma, Cat. No. G4527). 
7. Human chorionic gonadotropin (hCG; Sigma, Cat. No. C8554). 
8. KSOM medium (Millipore, Cat. No. MR-106-D). 
9. Reagents and equipment used for routine pronuclear microinjection are provided in the 
protocol on the University of California, San Diego Transgenic Mouse Core website 
(https://healthsciences.ucsd.edu/research/moores/shared-resources/transgenic-
core/services/Pages/pronuclear-injection.aspx).  
 
2.1.2 Genotyping and screening of targeted alleles 
1. Primers (Integrated DNA Technologies). 
2. 50 mM NaOH. 
3. 1 M Tris-HCl (pH 8.0). 
4. Taq PCR Kit (New England BioLabs, Cat. No. E5000S). 
5. Agarose (Thermo Fisher). 
6. TAE buffer (Thermo Fisher). 
7. Zero Blunt TOPO PCR cloning kit (Thermo Fisher, Cat. No. K2830-20). 
8. LB plates containing 50 µg/mL Kanamycin. 
 
2.2  Maintenance of mouse stains and generation of conditional knockout and mutant mice 
1. Mice. C57BL/6 J (The Jackson Laboratory).  
2. Flpase deleter mice (Rodriguez et al., 2000).  
3. Appropriate striated muscle-specific Cre expressing mouse line (see Table 1). 
 
2.3 Induction of Cre expression 
 
2.3.1 Tamoxifen  
Chow containing 0.4-1 g/kg tamoxifen. 
Water containing 0.5-1 mg/mL tamoxifen. 
Sesame oil containing 10 mg/mL tamoxifen. 
 
2.3.2 Doxycycline  
Water containing at 1-2 mg/mL doxycycline. 
 
2.4 Analysis of hearts 
 
2.4.1  Echocardiographic analysis of cardiac function  
1. Electric razor. 
2. Hair removal cream (Nair). 
3. Echocardiography machine (FujiFilm Visualsonics 2.0) with heating pad and electrodes. 
4. Echo software. 
5. Echo gel. 
6. Isofluorane. 
 
2.4.2  Sample preparation 
1. Heparin (1000 U/mL). 
2. Ketamine (100 mg/kg). 
3. Xylazine (10 mg/kg). 
4. Insulin needles. 
5. Fine scissors (FST, Cat. No. 14094-11). 
6. Extra fine Graefe forceps (FST, Cat. No. 11152-10). 
7. Ice cold Phosphate Buffered Saline (PBS). 
 
2.4.3  Measurement of heart weight:tibia length and heart weight:body weight ratios 
1. 70% Ethanol. 
2. Medium size forceps. 
3. Vernier Calipers (Kingsmart 6 inch LCD Digital /Micrometer Gage 150 mm). 
 
2.4.4  Immunofluorescence analysis 
1. Cryostat (Thermo Cryostar NX70). 
2. Cryostat blades. 
3. Wax pen (Immedge, Vector labs). 
4. Superfrost Plus slides (VWR, Cat. No. 631-0108). 
5. Humidified slide-incubation chamber. 
6. Thickness 1.5 coverslips (VWR, Cat. No. 631-0138). 
7. Inverted confocal microscope (Olympus FV-1000). 
8. PBS. 
9. Acetone (Sigma). 
10. 4% paraformaldehyde (PFA) in PBS (wt/vol). 
11. Optimal cutting temperature (OCT) compound. 
12. Sucrose. 
13. Dry ice. 
14. 3% Bovine Serum Albumin (99.5% pure) in PBS. 
15. Normal Donkey Serum. 
16. DAKO mounting medium. 
17. Clear nail polish. 
18. Vectashield mounting medium. 
19. 0.2% Triton-X100 in PBS (PBS/T). 
20. Relevant antibodies (see Table 2). 
 
2.4.5  Histological preparation for chemical staining 
1. Tissue cassettes. 
2. Wide-necked Erlenmeyer flask. 
3. Glass histology staining chambers. 
4. Microtome (Leica RM2125RTF). 
5. Water bath. 
6. Oven. 
7. Ethanol. 
8. Xylene. 
9. 10% neutral buffered Formalin. 
10. 4% PFA in PBS. 
11. Paraffin. 
12. Hematoxylin and eosin stain. 
13. Masson’s Trichrome stain. 
14. Brightfield microscope (Keyence BZX-700). 
 
2.4.6  RNA extraction 
1. RNA extraction kit (Promega RNA miniprep kit). 
2. cDNA synthesis kit (Thermo Superscript III). 
3. Quantitative Real-time PCR machine (Thermo StepOnePlus). 
4. Primer pairs (see Table 3). 
 
2.4.7  Protein extract preparation 
1. Pestle and mortar. 
2. Sonicator. 
3. Spatula. 
4. Western blotting apparatus. 
5. Liquid nitrogen. 
6. Lysis buffer: 8 M Urea, 2 M Thiourea, 3% SDS (wt/vol), 75 mM DTT, 0.03% Bromophenol 
Blue (wt/vol), 50 mM TRIS-HCL pH6.8. 
 
2.5 Analysis of skeletal muscle 
 
2.5.1  Preparation of tools for TA muscle fiber isolation 
1. P200 tips. 
2. Bunsen burner. 
3. Razor blade. 
4. 0.2% Triton-X100 in PBS (PBS/T). 
5. Superfrost Plus slides. 
6. Wax pen. 
 
2.5.2  Extraction of TA muscle from leg 
1. Dissection microscope (Leica M80). 
2. Lightsource (Schott KL1500LCD). 
3. Dumont #5 fine forceps (FST, Cat. No. 11254-20). 
4. Spring scissors (FST, Cat. No. 15009-08). 
5. Dumont AA polished forceps (FST, Cat. No. AA INOX). 
6. 4% PFA in PBS. 
 
2.5.3  Analysis of myonuclear positioning and immunofluorescence staining 
1. Thermomixer (Eppendorf Thermomixer F). 
2. Superfrost Plus slides. 
3. Thickness 1.5 coverslips. 
4. DAKO mounting medium. 
7. Wax pen. 
5. 10 M NaOH. 
6. PBS. 
7. DAPI. 
8. 3% Bovine Serum Albumin (99.5% pure) in PBS. 
9. Normal Donkey Serum. 
10. 0.2% Triton-X100 in PBS (PBS/T). 
11. Relevant antibodies (see Table 2). 
 
3. Methods 
 
3.1 CRISPR/Cas9-mediated gene manipulation to create floxed and point mutation mice with a 
cloning-free method 
 
3.1.1 CRISPR/Cas9 targeting design 
1. For design of the guide CrRNA, follow the protocol described by the Zhang laboratory (Ran 
et al., 2013). Briefly, input the target genomic DNA sequence into the online CRISPR Design 
Tool: http://crispr.mit.edu/. The CRISPR Design Tool takes an input sequence (for example, 
a 1 kb genomic fragment from the region of interest), identifies and ranks suitable target 
sites, and computationally predicts off-target sites for each intended target. Alternatively, 
one can manually select guide sequences by identifying the 20 bp sequence directly 
upstream of a protospacer adjacent motif (PAM) sequence (5′-NGG) (Ma et al., 2017) 
(Figure 2B). 
2. For conditional allele generation, two sgRNAs are designed to elicit DSBs that flank the 
sequence to be deleted. In addition, an ssDNA oligo is designed that contains the 
corresponding loxP site flanked by two 40- to 60-base homology arms that correspond to 
the sequence surrounding each sgRNA-mediated DSB (Figure 2B). 
3. To introduce a point mutation, in addition to the sgRNA targeting the site of interest, an 
ssDNA oligo is designed that contains the desired alteration flanked on each side by 40-60 
bases that are homologous to the sequences directly upstream and downstream of the DSB. 
 
3.1.2 Zygote preparation and microinjection 
1. Inject 12-15 female C57BL/6 J (3-4 weeks old) mice with PMSG (5 IU) at 1:00-2:00 p.m. on 
day 1. 
2. After 48 hours, inject female mice with hCG (5 IU). After hCG injection, house female mice 
with C57BL/6 J male mice overnight. 
3. Prepare the medium for embryo culture. Place several drops (30-50 μL for each drop) of 
KSOM medium on a 6-cm dish and cover with mineral oil, place the dish into a 37°C 
incubator for at least 30 minutes before use. 
4. At 20-21 hours after hCG injection, euthanize the mice and collect zygote-cumulus 
complexes from the oviduct where it is most swollen. 
5. Move the zygote-cumulus complexes into M2 + Hy medium, gently triturate 3 times with a 
P200 tip. 
6. Gently aspirate complexes with a transfer pipette, wash 3 times in M2 medium and place the 
embryos into KSOM medium at 37°C in a 5% CO2 incubator. 
7. Prepare the injection mix: Cas9 protein, crRNA and tracrRNA, with or without ssODN 
(experiment dependent) and mix in IDTE buffer (IDT, Coralville, IA, USA) to a working 
concentration of 30 ng/μL, 0.6 pmol/μL, 0.6 pmol/μL, and 20 ng/μL, respectively. Incubate the 
mixture at 37°C for 5 minutes (Figure 2A). 
8. The standard protocol describing pronuclear microinjection is provided on the University of 
California, San Diego Transgenic Mouse Core website 
(https://healthsciences.ucsd.edu/research/moores/shared-resources/transgenic-
core/services/Pages/pronuclear-injection.aspx). 
 
3.1.3 Primer design, genotyping, and screening of targeted alleles 
1. Primer design: To screen for correctly targeted point mutation mice, a mutation-specific 
forward primer is designed with the site-specific variant sequence at the 3’ end, and a 
generic wildtype reverse primer is used (Ma et al., 2017) (Figure 2D). To detect floxed 
alleles, a LoxP-specific and wildtype primer pair are designed. 
2. Genomic DNA preparation:  
(1) Collect tail biopsies from 3-week-old mice and add 300 μL of 50 mM NaOH. 
(2) Incubate at 98°C for 30 minutes, then add 50 μL of 1 M Tris-HCl (pH 8.0). 2 μL of 
genomic DNA sample is used for genotyping PCR. 
3. Genotyping PCR of F0 founders:  
(1) Amplify the extracted DNA using gene-specific primers under the following conditions: 
30 cycles at 94°C for 20 seconds, 60°C for 20 seconds. and 72°C for 30 seconds. 
(2) Run the PCR product on a 2% (wt/vol) agarose gel in TAE buffer to verify that the 
product is unique and of the expected size.  
4. PCR for sequencing validation of mutated alleles of F0 founders: 
(1) PCR amplify the extracted genomic DNA using primers flanking the targeted region. 
(2) Clone the PCR product using a Zero Blunt TOPO PCR cloning kit according to 
manufacturer's instructions. 
(3) To validate mutant alleles, extract plasmid DNA from 6 individual colonies and sequence 
(Note 5). 
 
3.2 Maintenance of mouse stains and generation of conditional knockout and mutant mice 
1. Breed F0 mutant mice with wildtype C57BL/6 J mice. 
2. The first generation offspring (F1) from each founder are subjected to genotyping using PCR 
and are sequenced to confirm germline transmission (as described in Section 3.1.3) (Note 
6). 
3. Cross F1 mutant heterozygous mice with wildtype C57/B6J mice to maintain the mutant line.   
4. Floxed (f/f) females are mated with Cre-positive (+/+; Cre+) males to generate f/+; Cre+ 
mice. Floxed females are then mated with f/+; Cre+ males to generate tissue-specific 
knockout mice (f/f; Cre+) (CKO) and their control littermates (f/f) and (f/+; Cre+) (Note 7, 8). 
5. Heterozygous mutant (m/+) females are mated with CKO (f/f; Cre+) males to generate cell 
selective specific mutant mice (f/m; Cre+) (CMUT). CMUT males are bred with homozygous 
floxed (f/f) females to generate CMUT (f/m, Cre+) and littermate controls (Figure 3) (Fang et 
al., 2017b).  
 
3.3 Induction of Cre expression 
Tamoxifen can be administered via food (custom-made chow containing 0.4-1 g/kg tamoxifen, Harlan), 
water intake (0.5-1 mg/mL) or 1-5 consecutive days of intraperitoneal injection (0.03-0.09 mg/g body 
weight) (Koitabashi et al., 2009; Sohal et al., 2001). Doxycycline is administered in drinking water at 1-2 
mg/mL (Rao and Monks, 2009; Wu et al., 2010). 
 
3.4 Analysis of hearts  
 
3.4.1 Echocardiographic analysis of cardiac function 
1. Weigh mouse. 
2. Shave the middle and the left-hand side of the chest on the underside of the mouse with a 
small electric razor (see Figure 4A). 
3. Using a q-tip, place a small amount of hair-removal cream on the chest around the center 
and to the left of the rib cage on the underside of the mouse (Note 9). Leave for 10-20 
seconds then using a surgical swab, wipe off the hair removal cream and hair. Wipe the 
chest with a wet surgical swab to remove the excess hair removal cream and hair. 
4. Place mouse in supine position on pre-warmed echo pad at 39C. 
5. Place 1 electrode on the right leg and another on the right arm to measure heart rate. 
6. Tape the limbs to the pad. 
7. Anaesthetize the mouse using a quick burst of 5% isofluorane in oxygen for a few seconds. 
8. Once anesthetized, reduce to 0.5% isofluorane to ensure the heart rate is maintained above 
500 beats per minute (Note 10). 
9. Squeeze a 4 mm cylinder of conductive echo gel on the probe to be used for 
echocardiography (use a 45 MHz probe). 
10. Place the probe on the chest and locate the heart (Note 11).  
11. For a 4-chamber (or long axis) view using B-mode, place the probe perpendicular to the 
chest at approximately a 45 angle to make an imaginary line between the right arm and 
middle of the left side of the abdomen (see Figure 4A, left). 
12. For a 2-chamber (or short axis) view or short axis using M-mode rotate the probe by 90 to 
make an imaginary line between the left arm and middle of the right side of the abdomen 
(see Figure 4A, right). 
13. Images are taken at the level of the papillary muscles, which are very prominent, echogenic 
regions (appear white) in mouse hearts. 
14. Record 3 consecutive cycles of diastole (during heart relaxation) and systole (heart 
contraction). 
15. Remove the excess echo gel and place the mouse back in cage. 
16. Download the echo images and perform analysis on a computer with Vevo 2100 software 
installed. 
17. Measure the left ventricle chamber sizes, called the Left Ventricle Internal Dimension (LVID), 
and Inter-Ventricular Septum (IVS) wall thickness and Left Ventricle Posterior Wall (LVPW) 
thickness in diastole and systole, then calculate the mean values between the 3 beats (see 
Figure 4B) (Note 12).  
18. Left ventricle systolic function is measured using the parameter called Fractional Shortening, 
which is measured as a percentage of the amount the chamber sizes change between 
systole and diastole divided by the chamber size in diastole (FS= [LVIDd-LVIDs]/ LVIDd). 
 
3.4.2  Sample preparation 
1. Weigh the animal. 
2. Intraperitoneal inject 0.2 mL heparin (1000 U/mL) (Note 13). 
3. Open up the chest by cutting around the edge of the rib cage to avoid cutting the heart. 
4. Using forceps grip the base of the heart and with sharp scissors excise the heart above the 
aorta to avoid cutting the atria. 
5. Rinse heart in ice cold PBS to remove excess blood. 
6. Remove the aorta and other non-cardiac tissue. 
7. Briefly dry the heart using a surgical swab. 
8. Weigh the heart on a fine balance. 
9. Using a scalpel blade dissect the heart into 4 pieces (see Figure 5A-B) (Note 14, 15). 
10. Place the middle section in a glass vial containing 5 mL 10% neutral buffered formalin and 
fix at 4C overnight for histology (see Section 3.4.5). 
11. Snap freeze the two apical halves in liquid nitrogen (for RNA and protein analysis, see 
Sections 3.4.6 and 3.4.7). 
12. Take tail biopsy for genotype confirmation and snap freeze. 
 
3.4.3  Measurement of heart weight:tibia length and heart weight:body weight ratios 
1. Spray the lower legs with 70% ethanol to dampen the hair. 
2. Using medium size forceps or between fingers grab one of the feet. 
3. With a pair of medium size sharp-ended forceps, pierce and grab the skin above the foot 
and pull skin over the front of the knee joint to expose the patella tendon (shiny, almost 
metallic-looking strip that is approx. 1 mm wide by 5 mm long) that runs over the front of the 
knee (Note 16). 
4. Using Vernier calipers, measure the distance between the middle of the exposed patella 
tendon and the bottom of the ankle (see Figure 5C). 
5. Divide heart weight by tibia length or body weight for global indices of cardiac hypertrophy 
(Note 17). 
 
3.4.4  Immunofluorescence analysis 
1. Place the base of the heart in isopentane to dehydrate (Note 18). 
2. Remove after 30-60 seconds and place in a small pool of OCT compound on a sectioning 
mold. 
3. Place the mold on a block of dry ice, and let the tissue/OCT slowly freeze into place. 
4. Slowly fill the mold with OCT; making sure the orientation of the heart does not change until 
the mold is filled with OCT. 
5. Use immediately or store at -80C until ready for sectioning. 
6. Before sectioning place the mold in the Cryostat at -20C to warm up the section to -20C 
(Note 19). 
7. Label slides with date, genotype, slide number. 
8. Using a new blade cut 10 μm sections sequentially using a separate slide for each section 
cut (see Figure 5D) (Note 20, 21). 
9. Allow sections to dry. 
10. Place in -80C freezer. 
11. Remove sections and immediately place in -20C acetone at -20C to fix sample for 5 
minutes (Note 22). 
12. Remove and wash section with PBS. 
13. Permeabilize sections with PBS containing 0.2% Triton-X100 at room temperature for 15 
minutes. 
14. Use wax pen to draw around individual sections to allow for use of multiple antibodies/slide. 
15. Incubate antibodies overnight in PBS containing 3% BSA, 2% Normal Donkey Serum at 4C 
in humidified slide-incubation chamber (Note 23). 
16. Wash 3x for 10 minutes with PBS. 
17. Incubate with relevant secondary antibodies for 1 hour at room temperature in a humidified 
slide-incubation chamber. 
18. Wash 3x for 10 minutes with PBS. 
19. Stain with DAPI for 5 minutes at room temperature. 
20. Wash 3x for 10 minutes with PBS. 
21. Add Vectashield dropwise to sections (Note 24).  
22. Carefully place coverslip (type 1.5 high tolerance) down at one end of the slide holding the 
other end up with forceps, then slowly lower the forceps (see Figure 5D) (to avoid 
generating air bubbles). 
23. Let solidify overnight at 4C. 
24. Image on confocal microscope/deconvolution microscope. 
 
3.4.5  Histological preparation for chemical staining 
1. After fixing the heart overnight at 4C wash 3x in PBS. 
2. Label the tissue cassette using a pencil (Note 25). 
3. Prepare molten paraffin wax by placing paraffin in a bottle in an incubator set to 55-65C. 
4. Remove tissue from glass vial and transfer to tissue cassette. 
5. Place cassettes in an Erlenmeyer flask (with a neck wide enough to slot the cassettes in) or 
beaker containing 70% ethanol (filled as necessary to completely cover the cassettes) and 
wait 20 minutes. 
6. Replace 70% ethanol with 95% ethanol and wait 20 minutes. 
7. Remove 95% ethanol and replace with fresh 95% ethanol and wait 20 minutes. 
8. Remove 95% ethanol and replace with 100% ethanol and wait 20 minutes. 
9. Remove 100% ethanol and replace with fresh 100% ethanol and wait 20 minutes. 
10. Remove 100% ethanol and replace with zylene and wait 20 minutes. 
11. Remove zylene and replace with fresh zylene. 
12. Open cassette and pour molten paraffin wax into the cassette. 
13. Carefully adjust the orientation of the heart to ensure a 2-chamber view. 
14. Allow paraffin to set around tissue. 
15. Turn on waterbath at 35-40C. 
16. Mount hardened section on Microtome with new blade attached. 
17. Cut 5 μm sections and place sections on the surface of the water in the bath. 
18. Immerse the slide below the floating section and scoop up the section onto the slide. 
19. Place slide in an oven at 65C for 10-15 minutes to melt the paraffin and mount the section 
to the slide. 
20. Remove slide. 
21. Stain slides with commercially available staining kits for Hematoxylin and Eosin (nuclei, dark 
blue/violet; tissue, red/pink) or Masson’s Trichrome (nuclei, dark red/purple; tissue, red/pink; 
collagen, blue). 
 
3.4.6  RNA extraction 
1. Take half of the apical section of the heart (Figure 5A). 
2. Extract RNA using the Promega RNA mini-prep kit (or equivalent). 
3. Generate cDNA using a reverse transcription kit. 
4. Perform quantitative real-time PCR using primers listed in Table 3. 
 
3.4.7  Protein extract preparation 
1. Pre-chill pestle and mortar with liquid nitrogen. 
2. Take half of the apical section of the heart (Figure 5A) out of liquid nitrogen. 
3. Weigh tissue. 
4. Calculate volume of lysis buffer needed to achieve 50 μL/mg tissue (Note 26). 
5. For tissue weighing >6 mg: place frozen tissue in mortar and add 300 μL lysis buffer (the 
lysis buffer will freeze, you want to keep everything frozen during this process, more liquid 
nitrogen can be added gently if necessary). 
6. For tissue weighing <6 mg, add the calculated volume of lysis buffer and continue as below. 
7. Homogenize tissue and lysis buffer with pestle and mortar into a fine powder. 
8. Use a spatula to scrape the powdered lysate into a 2.0 mL tube. 
9. Put sample on ice. 
10. Sonicate sample to shear DNA, until the lysate is easy to triturate. 
11. Add remaining lysis buffer to top up to the calculated volume necessary for 50 μL/mg. 
12. Triturate 3x to mix lysis buffer. 
13. Spin at 17,000G for 15 minutes. 
14. Aspirate supernatant. 
15. Aliquot into working aliquots of 300 μL and snap freeze in liquid nitrogen, snap freeze the 
remaining lysate. 
16. Use for Western blot or other downstream analysis. 
 
3.5 Analysis of skeletal muscle 
 
3.5.1 Preparation of tools for TA muscle fiber isolation 
1. Before starting, prepare some pipette tips to handle the fibers and a ‘dissection slide’ for the 
dissection of individual fibers. These steps are important to avoid losing a lot of fibers in the 
pipette tip and also to avoid contaminating your samples with plastic contaminants. 
2. Cut the end from a P200 tip using a razor blade (not scissors), then under a gentle Bunsen 
Burner flame, flame the edges of the cut tip (see Figure 5E) (Note 27). Rinse the P200 tip 
with PBS/Triton mix to prevent fibers sticking to the inside of the tip.  
3. Prepare a ‘dissection slide’ by drawing a square in the middle of a glass slide with a wax 
pen and leave to dry. This slide will be used to tease apart the individual fibers in a pool of 
PBS/T. 
  
3.5.2 Extraction of TA muscle from leg 
1. Cut the whole legs from an E18.5 or neonatal pup and place each in 1 mL of 4% PFA. 
2. Fix the samples overnight at 4C. 
3. Wash legs with PBS 3x to remove the PFA. 
4. Remove the skin from the leg using fine forceps. 
5. Using a dissection microscope, remove the fascia (thin membrane) surrounding the TA 
muscle by piercing it and dragging it away from the muscle with sharp, fine forceps. 
6. Slide the fine forceps in between the tibia bone and the TA muscle at the front of the shin. 
7. Cut/remove the tendons (shiny structures connecting the end of the muscle to bone) with 
fine scissors (Note 28). 
 
3.5.3 Analysis of myonuclear positioning 
1. Place a 0.5 mm x 2 mm strip of the TA muscle in 200 μL of 10 M NaOH in a 1.5 mL 
microcentrifuge tube. 
2. Place in a thermomixer set to 1000 RPM at 20C for 20-30 minutes depending on the size of 
the TA fragment. Alternatively, a regular vortex can be used, and pulsed until the fibers start 
to separate. 
3. Inspect the fibers every 10 minutes to look at the progress of fiber separation. 
4. Allow fibers to settle by gravity. 
5. Wash 5x with 1 mL PBS to remove the NaOH. 
6. Resuspend in 200 μL of PBS and add DAPI for 5 minutes. 
7. Wash 3x for 5 minutes with PBS. 
8. Using a wax pen, draw around the edges of the slide and leave to dry (so that you won’t 
lose any fibers when you squash the coverslip down on the fibers). 
9. Remove as much PBS as possible leaving ~20 μL. 
10. Resuspend fibers in an equal volume of DAKO mounting medium. 
11. Pipette the fibers directly onto the slide, spreading them along the length of the slide. 
12. Lower the coverslip and seal with nail polish. 
13. Image on a confocal or wide-field deconvolution microscope. 
14. Nuclear lengths and internuclear distances were measured using ImageJ software. In brief, 
for internuclear distances, a line was drawn between the nuclear centroid to centroid; for 
nuclear lengths, a line was drawn along the axis of the myofiber between the shortest widths 
of the nuclei (Stroud et al., 2017). 
 
3.5.4 Immunofluorescence staining 
1. Pipette a pool of PBS containing 0.2% TritonX-100 (PBS/T) into the square on the 
‘dissection slide’. Place the fiber in the center of the square containing PBS/T. 
2. Using two very small/fine forceps, tease apart the fibers into the smallest bundles as best 
you can. It will take about 1 hour per TA muscle, which will yield plenty of fibers for staining, 
therefore only about half of the TA muscle will be required and 3-4 per genotype. 
3. It is important to keep the fibers wet during this process, as they will dry up if left. 
4. Once you have dissected a good number of fibers, using the pipette tips prepared earlier, 
transfer the fibers into a 1.5 mL micro-centrifuge tube. 
5. The amount of fibers should come to about the 200 μL marker line on the side of the tube. 
This will provide enough fibers for up to six antibody stainings. 
6. Resuspend the fibers in an equal volume of PBS/T (~400 μL total including fibers). 
7. Aliquot the fibers according to the number of antibody stainings required. You may want to 
store a number of dissected fibers in the fridge in case problems are encountered or it 
requires optimization. 
8. Dilute the antibodies in 4% BSA/PBS/T at double the concentration to the recommended 
dilution. 
9. Add the antibody mix to an equal volume of the fibers (this will lead to the recommended 
dilution). 
10. Put on rotator overnight at 4C. 
11. In the morning, wash with PBS/T 3x for 5 minutes. For the washes, DO NOT spin the fibers 
in a centrifuge, let them settle by gravity. 
12. Add secondary antibodies for 1 hour and DAPI using the same procedure as primary 
antibodies. 
13. Wash 3x for 5 minutes with PBS. 
14. Using a wax pen, draw around the edges of the slide and leave to dry (so that you won’t 
lose any fibers when you squash the coverslip down on the fibers). 
15. Resuspend the fibers in an equal volume of DAKO mounting medium (about 10-15 μL/slide). 
16. Pipette the stained fibers on to the center of the slide (about 10-15 μL/slide). 
17. Separate the fibers around the slide (you want to avoid clustering in the center of the slide). 
18. Lower a large, rectangular coverslip onto the fibers avoiding bubbles. 
19. Seal the coverslip with nail varnish. 
20. Image using a confocal microscope or widefield deconvolution microscope (Note 29). 
 
4. Notes 
 
(1) It is important to check for LacZ expression on a mouse line-by-line basis, as some of the mutant 
alleles don’t express LacZ. 
 
(2) For homologous recombination to occur, a minimum of 2 kb of sequence homology is required 
(Melton, 2002). 5 to 14 kb of sequence homology is typical for targeting constructs. The availability of 
suitable restriction enzymes within the locus of interest and the sizes of inserted DNA fragments are 
common limitations of conventional cloning strategies. The following restriction enzymes are suitable 
for digesting genomic DNA of ES cells for Southern blotting: BamHI, HindIII, Acc65I/KpnI, EcoRV, SpeI, 
StuI, BglI.  
 
(3) Upon deciding which exon to flox, ideally, the loxP site should be more than 250 bp away from 
splice donor and acceptor sites. We also try and avoid floxing exon 1, and exons that are divisible by 3 
(so to avoid potential frameshift mutations). 
 
(4) Note that the conditional mutant mice have the genotype “-/m” in the tissue that the Cre is 
specifically expressed in, and “f/m” genotype in other tissues. 
 
(5) CRISPR/Cas9 injection in mouse zygotes may introduce mosaicism as the Cas9 enzyme may be 
active after the single cell stage (Yen et al., 2014). However, in our cloning-free method there were no 
cases of mosaicism observed (Ma et al., 2017). 
 
(6) It is important to be aware that the CRISPR/Cas9 approach may introduce off-target mutations. 
Therefore, in addition to sequencing the predicted off-target loci, mutant mice should be backcrossed 
with wildtype mice to dilute potential off-target effects, and at least two independently generated lines 
should be used per genotype. 
 
(7) Depending on the mouse background, litter sizes can vary. Therefore, the number of animals set up 
for breeding should be adjusted according to preliminary breeding data. 
 
(8) To avoid the unexpected (non-specific or broader expression) pattern of Cre, we utilize male Cre 
carriers crossed with floxed females. 
 
(9) It is important to remove as much hair as possible as hair can interfere with the echo signal. 
 
(10) The cardiac function measurement will be dramatically reduced due to the artefact of a low heart 
rate). 
 
(11) Because results can vary between operators, we recommend using a trained sonographer who is 
blinded to the genotypes and the mice be randomized prior to performing the echo. This will ensure 
better reproducibility, which is essential for robust examination of cardiac function in a serial study. 
 
(12) For echocardiography physiological measurements, we usually observe standard deviation of 10% 
between mice of the same genotype. With this assumption, 6-12 mice per group will be needed to 
measure a 14-22% change in heart function, to ensure robust analysis of statistical significance 
(P<0.05 using two-tailed t-test, with a power of α90%). A useful resource for calculating numbers 
required for physiological analyses: http://www.3rs-
reduction.co.uk/html/6__power_and_sample_size.html 
 
(13) Heparin is used to prevent blood clotting in the heart. 
 
(14) To make full use of the animals in line with the 3Rs policy, once the defined end-point for cardiac 
function has been performed, hearts can be processed for Western Blotting, Histology, 
Immunofluorescence and RNA analyses. 
 
(15) It is important to always check where your molecule of interest is expressed in the heart by 
performing immunofluorescence analysis on a wildtype 4-chamber view heart section. 
 
(16) To measure tibia lengths, it is also possible to dissolve the whole leg at room temperature over 
several days in 10 M NaOH. However, this involves handling caustic NaOH, and produces an 
unpleasant odor and therefore should be performed in a fume cupboard. 
 
(17) Measuring tibia length is preferred to body weight for measuring cardiac hypertrophy owing to 
greater fluctuations in body weight over time. 
 
(18) It is also possible to perform sucrose gradients to dehydrate the heart. Start with 10% sucrose 
(wt/vol) followed by 12%, 16%, and 20% sucrose. For each step, incubate in sucrose for a sufficient 
amount of time until the heart sinks to the bottom of the tube. For the final step incubate briefly with a 
1:1 ratio of 20% sucrose:OCT before embedding on dry ice. 
 
(19) Place OCT/heart block in the cryostat set to -20C prior to sectioning to soften the section, 
otherwise sections can be brittle if sectioned immediately after removal from a -80C freezer. 
 
(20) For sectioning, an anti-roll plate or fine paint brush can be used to prevent the section from folding 
back upon itself. 
 
(21) By putting sequential sections on sequential slides it allows comparison of multiple antibodies at 
approximately the same region of heart (within 10 μm of each other). 
 
(22) It is also possible to fix with 4% PFA, but this is antibody dependent. 
 
(23) Incubation times can be varied as required, but we found the antibodies listed in Table 2 work best 
with overnight incubation at 4C. 
 
(24) Other mounting media can be used at this step. The benefit of using Vectashield is that it has a 
well-defined refractive index of 1.45, which is important to know for super-resolution imaging. 
 
(25) Use pencil to mark slides as markings from most pens will be erased by further processing steps. 
 
(26) Heart tissue is very proteinaceous and therefore requires well-diluted samples to run on SDS-
PAGE gels. 
 
(27) It is important to prepare P200 tips in this manner as it will minimize the myofibers from becoming 
stuck inside the tip and therefore loss of precious material. 
 
(28) Removing the contaminating tendon will make teasing the muscle fibers apart much easier. 
 
(29) If no sarcomeric marker is available (such as sarcomeric alpha actinin), be sure to take a 
differential interference contrast or phase/contrast image. 
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Figure Legends 
 
Figure 1. Mouse generation strategies. (A) Mice obtained from the International Mouse Phenotype 
Consortium (IMPC) can be crossed with Sox2-Cre mice to generate global knockout mice. Alternatively, 
they can be crossed with flipase deleter mice to generate the conditional allele followed by a tissue-
specific Cre deletion in the relevant tissue or cell type. (B) The traditional gene targeting approach 
inserts two 34 base pair sequences referred to as LoxP sites (red triangles) that flank either side of a 
critical exon in a gene of interest, and a Neomycin cassette for embryonic stem (ES) cell selection. 
Diptheria Toxin A gene is incorporated outside of the homology arms to select against ES colonies that 
have not taken up the insert by homologous recombination. A new restriction enzyme site is introduced 
in the mutant construct to aid screening with Southern blotting. (C) Traditional gene targeting approach 
to generate the substitution mutation from nucleotide X to Y in an exon (blue).  
 
Figure 2. CRISPR/Cas9-mediated gene manipulation to generate floxed and point mutation  
alleles. (A) A cloning-free CRISPR/Cas9 system by pronuclear injection into a one-cell stage zygote of 
commercial Cas9 protein combined with chemically synthesized CRISPR RNA (crRNA), trans-
activating crRNA (tracrRNA), and single-strand oligodeoxynucleotides (ssODNs). (B) Schematic 
illustration to generate a conditional allele by insertion of two LoxP sites. In this method, two crRNAs 
are designed to direct the Cas9 to target the upstream and downstream introns of the target exon, 
along with corresponding LoxP site oligos with 60 bp homology sequences on either side surrounding 
each Cas9-mediated double-strand break. The protospacer adjacent motif (PAM) is shown in green. In 
the oligo donor sequence, the LoxP site is highlighted in yellow. (C) To generate point mutation mice, 
the sequence of the crRNA (red) targets the Cas9 nuclease to the desired mutation-specific region (in 
this example, CGG to CAT) of the target gene. The PAM is shown in green. (D) Design of the mutation-
specific primers with a site-specific variant sequence at the 3’ terminus of the forward primer to screen 
for correctly targeted mice. Figure modified from (Ma et al., 2017). 
 
Figure 3. Breeding strategy of conditional knock-in mice. 
 
Figure 4. Echocardiography recording and analysis. (A) Approximate positioning of 
echocardiography probe (orange rectangle) for a 2D long-axis B-mode view (left) and short axis M-
mode view (right). Dashed rectangle indicates the recommended area from which to remove hair. (B) 
Parasternal short axis M-mode with left ventricular functional measurements. Post capture, Left 
Ventricle Internal Dimension in diastole/systole (LVIDd/s); Left Ventricle Posterior Wall thickness in 
diastole/systole (LVPWd/s); Interventricular Septum thickness in diatole/systole (IVSd/s); Fractional 
Shortening (FS); Heart Rate (HR) are measured.  
 
Figure 5. Processing of heart for analysis. (A) Post-extraction, the heart is cut into three pieces: The 
base is used for immunofluorescence; the mid-section for histology; the apex is divided into two parts, 
for RNA and protein extraction. (B) Cross-sectional view of the heart showing all four chambers (top) 
and two chambers (bottom). (C) Schematic of a mouse tibia with measurement points indicated 
between the bottom of the tibia and the patella tendon. (D) Top view: After sectioning the heart for 
immunofluorescence analysis, sequential sections are placed on consecutive slides to allow direct 
comparison of different antibodies at similar spatial locations. Side view: Post-antibody staining and 
wash steps, a small amount of mounting medium is placed directly on the section and the coverslip is 
slowly lowered using forceps to avoid generating air bubbles. Depending on the mounting medium, 
coverslips are either left to dry overnight or sealed with clear nail polish. (E) Preparation of P200 tips to 
pipette isolated myofibers. Note the importance of using a razor blade and gentle Bunsen burner flame 
to generate smooth edges on the pipette tip to minimize sample loss. 
 
Tables 
 
Table 1. Cardiac and skeletal muscle-specific Cre lines 
Tissue 
Specificity 
Cre Line Expression 
Temporal 
Expression 
Spatial 
Efficiency Laboratory 
Source 
Original 
Reference 
Potential 
Caveats 
 
Cardiac  
Constitutive 
Alpha MHC E10.5 CMs 70% excision 
in adult CMs 
Abel (Abel et al., 1999) - 
Alpha MHC Low levels  
E8.0-E10.0 
CMs 70-80% excision 
by 3 weeks 
Schneider (Agah et al., 
1997) 
High expression level 
leads to DCM 
Beta MHC E12.5 CMs 70% excision 
by E17.5 
Yutzey and 
Molkentin 
(Parsons et al., 
2004) 
Expressed in somites 
and soleus muscle 
Nkx2.5 E8.0-E8.5 CMs 88% excision 
in adult CMs 
Olson (McFadden et al., 
2005) 
- 
Nkx2.5 E7.75-E8.0 CMs, pharyngeal 
endoderm 
High Harvey (Stanley et al., 
2002) 
- 
Nkx2.5 E7.5 CMs 100% excision 
by P1 
Schwarz (Moses et al., 
2001) 
Development of heart 
abnormalities 
cTnT E7.5-E10.5 CMs High Hogun (Jiao et al., 2003) Breeding problems in 
older mice 
XMLC2 E7.5-
adulthood 
CMs High Mohun (Breckenridge et 
al., 2007) 
- 
MLC2v E8.5 Ventricular CMs Low Chen (Chen et al., 
1998) 
- 
 
Inducible 
Cardiac 
MerCreMer-
Alpha MHC 
N/A CMs >80% excision 
after 5 days 
Molkentin (Sohal et al., 
2001) 
Cre toxicity observed 
at high levels 
MerCreMer-
cTnT 
N/A CMs High Cai (Yan et al., 2015) - 
Tet-TnT N/A CMs Not reported Zhou (Wu et al., 2010) - 
 
Constitutive 
Skeletal 
HSA E9.5 Skeletal muscle, some 
evidence in heart 
High Melki (Miniou et al., 
1999) 
Low level expression 
in the heart 
Myo E8.5 Skeletal muscle 
lineage 
>90% excision Olson (Li et al., 2005) - 
 
Inducible 
Skeletal 
HSA-MerCreMer - Skeletal muscle, some 
evidence in heart 
High Esser (McCarthy et al., 
2012) 
Low level expression 
in the heart 
HSA-Tet - Skeletal muscle Not reported Monks (Rao and Monks, 
2009) 
- 
CreRT2 lines - Various  Lepper (Southard et al., 
2014) 
- 
CMs, cardiomyocytes; E, embryonic day; MHC, Myosin heavy chain; Nkx2.5, Nk2 homeobox 5; cTnT, cardiac tropinin T, XMLC2, Xenopus 
Myosin Light Chain 2; MLC2V, Myosin light chain 2 (ventricular); MerCreMer, Mutated Estrogen Receptor; Dox, doxycycline; HSA, Human 
alpha Skeletal Actin, DCM, dilated cardiomyopathy 
 
 
Table 2. Recommended antibodies for detecting LINC complex proteins and sarcomeres 
Protein Company/ 
Source 
Cat. No./Clone Application Epitope Host Species 
and nature 
Validated with 
knockout tissue? 
Reference 
Nesprin 1 Glenn E Morris 7A12 WB and IF Human  
Nesprin 1α2 
Rabbit 
monoclonal 
Yes (Randles et al., 2010) 
SUN1 Millipore ABT285 WB Mouse  
C-terminus 
Rabbit 
polyclonal 
- (Banerjee et al., 2014) 
SUN1 Abcam ab103021 IF Mouse  
AAs 200-300 
Rabbit 
polyclonal 
- (Stroud et al., 2017) 
SUN2 Abcam EPR6557 WB and IF Human  
C-terminus 
Rabbit 
monoclonal 
- (Stroud et al., 2017) 
LUMA Abcam EPR15378 WB and IF Human  
AAs 100-200 
Rabbit 
monoclonal 
Yes Stroud et al (unpublished 
observations) 
Emerin Novocastra NCL-EMERIN (4G5) IF Human  
N-terminus 
Mouse 
monoclonal 
- (Huber et al., 2009) 
Emerin Santa Cruz sc-15378 (FL-254) WB Human  
AAs 3-254 
Rabbit 
polyclonal 
- (Stroud et al., 2017) 
LEM2 Sigma HPA017340 WB and IF Human AAs 
243-361 
Rabbit 
polyclonal 
Yes Stroud et al (unpublished 
observations) 
Sarcomeric 
α-actinin 
Sigma A7811 WB and IF Rabbit skeletal 
α-actinin 
Rabbit 
polyclonal 
- (Zhang et al., 2015) 
WB, western blot; IF, immunofluorescence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Sequences of qRT-PCR primers used to detect fetal, pro-fibrotic, and reference genes 
 Forward Reverse 
Fetal genes  
ANP GATAGATGAAGGCAGGAAGCCGC AGGATTGGAGCCCAGAGTGGACTAGG 
BNP TGTTTCTGCTTTTCCTTTATCTGTC CTCCGACTTTTCTCTTATCAGCTC 
AMHC CTGCTGGAGAGGTTATTCCTCG GGAAGAGTGAGCGGCGCATCAAGG 
BMHC TGCAAAGGCTCCAGGTCTGAGGGC GCCAACACCAACCTGTCCAAGTTC 
 
Pro-fibrotic genes  
COL1A1 TCACCAAACTCAGAAGATGTAGGA GACCAGGAGGACCAGGAAG 
COL3A1 ACAGCAGTCCAACGTAGATGAAT TCACAGATTATGTCATCGCAAAG 
 
Early activator genes  
Egr-1 CCTATGAGCACCTGACCACA TCGTTTGGCTGGGATAACTC 
Iex-1 TTATAGGGTCGGTAAGACAGAGTTG GACGGAGTGTTACCCCTAATCTTAT 
c-fos AGCCCCTGTGTACTCCCGTG GCCTTGCCTTCTCTGACTGC 
c-jun TTCCTCCAGTCCGAGAGCG TGAGAAGGTCCGAGTTCTTGG 
c-myc ATGCCCCTCAACGTGAACTTC GTCGCAGATGAAATAGGGCTG 
 
Reference genes  
18S GGAAGGGCACCACCAGGAGT TGCAGCCCCGGACATCTAAG 
GAPDH CTCAAGATTGTCAGCAATGCATCC CCAGTGGATGCAGGGATGATGTTC 
Primers are in 5’ to 3’ orientation 
 
